TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12846595

Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (3mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ximelagatran (24mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Activated partial thromboplastin time (APTT) ratio
Number of subjects: 24
Study: 10958095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.3 mg x kg(‐1))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (1 mg x kg(‐1))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of dimenhydrinate and metoclopramide
Number of subjects: 160
Study: 8836333

Group type: EXPERIMENTAL
Intervention: Active treatment (local nasal immunotherapy with birch-alder allergens in powder form)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 22
Study: 1430296

Group type: EXPERIMENTAL
Intervention: Plax mouthwash
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 33
Study: 4072649

Group type: EXPERIMENTAL
Intervention: Meticillin 1 g X 4 intravenously on the day of operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 50
Study: 3310513

Group type: EXPERIMENTAL
Intervention: Ventilator rate of 120/min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ventilator rate of 120/min using Sechrist ventilators
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ventilator rates of 30/min and 60/min
Number of subjects: 32
Study: 30277101

Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 331
Study: 28768627

Group type: EXPERIMENTAL
Intervention: recombinant factor VIII (rFVIII)
Number of subjects: 235

Group type: COMPARATOR
Intervention: plasma-derived concentrates (pdFVIII)
Number of subjects: 235
Study: 25652341

Group type: EXPERIMENTAL
Intervention: Gaps‐In‐Noise test (GIN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Gap Detection Test (GDT)
Number of subjects: 31
Study: 23902481

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² administered once a week for 4 weeks)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclophosphamide followed by azathioprine (cyclophosphamide for 3 to 6 months followed by azathioprine for 12 to 15 months)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Rituximab (for patients with relapsing disease at baseline)
Number of subjects: 197
Study: 21816030

Group type: EXPERIMENTAL
Intervention: RTS, S/AS01 malaria vaccine
Number of subjects: 0
Study: 19394194

Group type: EXPERIMENTAL
Intervention: Direct Treatment Model (DT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Collaborative-Consultation Treatment Model (CC)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Combined Treatment Model (CT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 16928222

Group type: EXPERIMENTAL
Intervention: PBAT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin‐clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d.)
Number of subjects: 54

Group type: COMPARATOR
Intervention: PBMT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.)
Number of subjects: 54
Study: 15173146

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g monthly)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 11340690

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide 220 micrograms/day for six months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral cetirizine 10 mg/day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Intranasal beclomethasone dipropionate 400 micrograms/day
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 92
Study: 9325511

Group type: EXPERIMENTAL
Intervention: Patient Controlled Epidural Infusor (PCEA) using pethidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard electronic device for PCEA using pethidine
Number of subjects: 20
Study: 8076759

Group type: EXPERIMENTAL
Intervention: Interferon treatment (8.4-336 megaunits)
Number of subjects: 90
Study: 3065499

Group type: EXPERIMENTAL
Intervention: Insertion of a long-term ventilation tube
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (non-ventilated ear)
Number of subjects: 50
Study: 31464189

Group type: EXPERIMENTAL
Intervention: iMHere mobile health system
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard care without technology intervention
Number of subjects: 38
Study: 28848330

Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Lactobacillus paracasei N1115, 300 mL/d for 12 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Normal diet without probiotic supplementation
Number of subjects: 205
Study: 25187210

Group type: EXPERIMENTAL
Intervention: 0.1 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.4 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23261001

Group type: EXPERIMENTAL
Intervention: No significant CAD
Number of subjects: 127

Group type: COMPARATOR
Intervention: CAD
Number of subjects: 127
Study: 21711137

Group type: EXPERIMENTAL
Intervention: LMA StoneBreaker™ (SB)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Swiss LithoClast® (LC)
Number of subjects: 77
Study: 19359109

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17130977

Group type: EXPERIMENTAL
Intervention: Postoperative chemo radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macdonald study protocol
Number of subjects: 0
Study: 12757115

Group type: EXPERIMENTAL
Intervention: 30% long-chain triglycerides (phospholipid/triglyceride ratio: 0.04)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 20% long-chain triglycerides (phospholipid/triglyceride ratio: 0.06)
Number of subjects: 90
Study: 11486797

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Imaging (TCDI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transcranial Doppler (TCD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Imaging (TCDI) after modifications
Number of subjects: 29
Study: 9220523

Group type: EXPERIMENTAL
Intervention: Reported tobacco smoke exposure (mean number of cigarettes smoked per day in the infant's presence)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Urinary cotinine/creatinine ratio
Number of subjects: 485
Study: 8123410

Group type: EXPERIMENTAL
Intervention: i.v. clonidine 30 micrograms diluted in saline to a total volume of 5 ml, repeated every 5 min up to a maximum dose of 90 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline 5 ml (placebo solution), repeated every 5 min up to a maximum of three boluses
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (placebo) after initial clonidine treatment
Number of subjects: 40
Study: 3546120

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise for 60 minutes three times a week for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: No physical training
Number of subjects: 20
Study: 31039153

Group type: EXPERIMENTAL
Intervention: Single dose of linezolid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multiple doses of linezolid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Long-term linezolid treatment
Number of subjects: 48
Study: 29016675

Group type: EXPERIMENTAL
Intervention: Team sport group ingesting a drink high in protein (18 g) immediately and 3 h after each training session (TS-HP, n = 13)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Team sport group ingesting an isocaloric drink with low protein content (3 g; TS-LP, n = 18)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group continuing their normal activities (CON, n = 17)
Number of subjects: 48
Study: 25569128

Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring with a dedicated treatment guideline during the first 72 hours of life
Number of subjects: 166

Group type: COMPARATOR
Intervention: Blinded NIRS monitoring with standard care
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring
Number of subjects: 166

Group type: COMPARATOR
Intervention: Blinded NIRS monitoring
Number of subjects: 166
Study: 23686030

Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 5 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rACC activity assessment
Number of subjects: 22
Study: 21245735

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural (GAE)
Number of subjects: 226
Study: 19799601

Group type: EXPERIMENTAL
Intervention: Glycerol 855 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycerol 1710 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy individuals) 1710 mg/kg
Number of subjects: 20
Study: 16762943

Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fiber fraction of RMD
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 17
Study: 15334859

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 0
Study: 11502796

Group type: EXPERIMENTAL
Intervention: Recombinant human IGF-I (40 microg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9258804

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX)
Number of subjects: 9

Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 9
Study: 8506190

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 20
Study: 2891534

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam administered at 0900 h (day-time)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam administered at 2200 h (night-time)
Number of subjects: 12
Study: 29668919

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 27527391

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - initial dose of 1 µg/kg for 10 min followed by continuous infusion at 0.3 µg/kg/h until the end of surgery.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group - saline treatment.
Number of subjects: 80
Study: 24680359

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (ART) with 60 Gy
Number of subjects: 388

Group type: COMPARATOR
Intervention: Wait-and-see (WS)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (ART)
Number of subjects: 388
Study: 22686491

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections and abduction bracing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 46
Study: 20980426

Group type: EXPERIMENTAL
Intervention: Supervised walking sessions (3 times per week) and counseling
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard lifestyle recommendations
Number of subjects: 59
Study: 18828921

Group type: EXPERIMENTAL
Intervention: SNAG mobilisation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham mobilisation
Number of subjects: 49
Study: 16355089

Group type: EXPERIMENTAL
Intervention: SCD Express Compression System
Number of subjects: 12

Group type: COMPARATOR
Intervention: VenaFlow (rapid inflation device)
Number of subjects: 12
Study: 12002407

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement 1U/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement 2U/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10202820

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily and Saquinavir 400 mg twice daily, combined with Stavudine 40 mg twice daily and Lamivudine 150 mg twice daily.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nelfinavir-containing regimen (previous treatment).
Number of subjects: 26
Study: 7717552

Group type: EXPERIMENTAL
Intervention: Fentanyl 2.5 mcg/kg intravenous bolus followed by 1 mcg/kg/h infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 5.0 mcg/kg intravenous bolus followed by 2 mcg/kg/h infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl (both doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desflurane administration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol administration
Number of subjects: 30
Study: 1479654

Group type: EXPERIMENTAL
Intervention: Epidural infusion of buprenorphine 5 micrograms.ml‐1 at 1 ml.h‐1 (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.25% bupivacaine at 1 ml.h‐1 (group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of buprenorphine and bupivacaine at 1 ml.h‐1 (group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 6370145

Group type: EXPERIMENTAL
Intervention: 1.0 ppm SO2 during exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5 ppm SO2 or less
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.75 ppm SO2
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.00 ppm SO2 (control)
Number of subjects: 20
Study: 31518566

Group type: EXPERIMENTAL
Intervention: Honda's Stride Management Assist (SMA) exoskeleton
Number of subjects: 12
Study: 29356610

Group type: EXPERIMENTAL
Intervention: 8-week group psychosocial intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard care plus educational reading materials
Number of subjects: 194
Study: 25229216

Group type: EXPERIMENTAL
Intervention: 5 mg Sb(5+)/kg/day of intramuscular meglumine antimoniate (Sb(5+)) for 30 successive days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Montenegro skin test (MST)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Early treatment (defined as treatment applied for skin lesions less than two months old at the first appointment)
Number of subjects: 3
Study: 22981148

Group type: EXPERIMENTAL
Intervention: Urinary RBP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Urinary MCP‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Serum VEGF
Number of subjects: 56

Group type: COMPARATOR
Intervention: TGF‐β
Number of subjects: 56

Group type: COMPARATOR
Intervention: VEGF
Number of subjects: 56
Study: 19577983

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SYNTAX score assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-observer reproducibility
Number of subjects: 100
Study: 17239677

Group type: EXPERIMENTAL
Intervention: Exercise training (36 supervised sessions, transitioning to home-based exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 14965386

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Receiving preferred treatment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Not receiving preferred treatment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Randomised treatment preference
Number of subjects: 207
Study: 12117704

Group type: EXPERIMENTAL
Intervention: Average annualized weight loss of at least 1.6 kg/year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss between 1.6 and 0.7 kg/year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight gain of more than 0.5 kg/year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline body mass index of less than 23.6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referent group (weight stable and intermediate body mass index 23.6 to <28.0 kg/m2 and weight change (‐0.7 to <0.5 kg/year)
Number of subjects: 0
Study: 9737643

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025 mg/day
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.05 mg/day
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg/day
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg/day
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day (US)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day (Europe)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg twice daily
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg with evening meal
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg at bedtime
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 7918266

Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.3% norfloxacin
Number of subjects: 39
Study: 2456776

Group type: EXPERIMENTAL
Intervention: 10% cocaine solution (3-4 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study: 29979704

Group type: EXPERIMENTAL
Intervention: SMS promoting the availability of HIV self-testing (HIVST) kits
Number of subjects: 0

Group type: COMPARATOR
Intervention: General SMS reminding clients to test for HIV (enhanced and standard program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) option within the intervention arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per additional client tested for FSWs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per additional client tested for truckers
Number of subjects: 0
Study: 26354534

Group type: EXPERIMENTAL
Intervention: Baseline total percentage body fat
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Percentage trunk fat
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Percentage abdominal fat
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Higher baseline percentage trunk and abdominal fat
Number of subjects: 294

Group type: COMPARATOR
Intervention: Smaller percentages of fat in trunk and abdominal regions
Number of subjects: 294
Study: 23833849

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 micro g after spinal anesthesia)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin (after delivery of the baby)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 21092809

Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hand instrumentation technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RaCe rotary system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mtwo rotary system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 50
Study: 18320942

Group type: EXPERIMENTAL
Intervention: neobladder construction using the patient's intestinal tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sexuality-preserving surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: perioperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: chemo-radiation
Number of subjects: 0
Study: 16617756

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine + 3.3 microg sufentanil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 6.6 mg bupivacaine + 3.3 microg sufentanil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: levobupivacaine + 3.3 microg sufentanil
Number of subjects: 91

Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 91
Study: 14739715

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propafenone/Sotalol
Number of subjects: 0
Study: 10812893

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 4 Hz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 8 Hz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 4 Hz and 8 Hz with food intake (solid meal 80 g, 135 cm3, 400 kcal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) during food intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 10
Study: 8792887

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 25% TH
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 50% TH
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 10% TH
Number of subjects: 54
Study: 1569672

Group type: EXPERIMENTAL
Intervention: 1 gm cefonicid
Number of subjects: 107

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 107
Study: 3904243

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cimetidine (200 mg t.i.d. + 400 mg nocte)
Number of subjects: 80
Study: 31271261

Group type: EXPERIMENTAL
Intervention: Probiotic product (1.5 × 10^10 CFU/day) consisting of Lactobacillus acidophilus DDS‐1, Bifidobacterium animalis subsp. lactis UABla‐12, Bifidobacterium longum UABl‐14, and Bifidobacterium bifidum UABb‐10 over 4 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 30032120

Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients (3-month mRS 2-4)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients (examining BI and RMI)
Number of subjects: 234